ERBB2 and breast carcinoma: Despite progress in targeted therapies and personalized medicine, cytotoxic chemotherapy remains a cornerstone of treatment for early-stage breast cancer, particularly in high-risk subgroups such as node-positive, human epidermal growth factor receptor 2 (HER2)-positive, or triple-negative disease.